These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 26983879

  • 1. Differential Effects of PI3K and Dual PI3K/mTOR Inhibition in Rat Prolactin-Secreting Pituitary Tumors.
    Chanal M, Chevallier P, Raverot V, Fonteneau G, Lucia K, Monteserin Garcia JL, Rachwan A, Jouanneau E, Trouillas J, Honnorat J, Auger C, Theodoropoulou M, Raverot G.
    Mol Cancer Ther; 2016 Jun; 15(6):1261-70. PubMed ID: 26983879
    [Abstract] [Full Text] [Related]

  • 2. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
    Schrauwen S, Depreeuw J, Coenegrachts L, Hermans E, Lambrechts D, Amant F.
    Gynecol Oncol; 2015 Jul; 138(1):165-73. PubMed ID: 25933683
    [Abstract] [Full Text] [Related]

  • 3. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
    Fourneaux B, Chaire V, Lucchesi C, Karanian M, Pineau R, Laroche-Clary A, Italiano A.
    Oncotarget; 2017 Jan 31; 8(5):7878-7890. PubMed ID: 28002802
    [Abstract] [Full Text] [Related]

  • 4. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z, Xie G, Zhou G, Cheng Y, Zhang G, Yao G, Chen Y, Li Y, Zhao G.
    Cancer Lett; 2015 Oct 10; 367(1):58-68. PubMed ID: 26188279
    [Abstract] [Full Text] [Related]

  • 5. Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines.
    Mueller A, Bachmann E, Linnig M, Khillimberger K, Schimanski CC, Galle PR, Moehler M.
    Cancer Chemother Pharmacol; 2012 Jun 10; 69(6):1601-15. PubMed ID: 22543857
    [Abstract] [Full Text] [Related]

  • 6. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
    Shoji K, Oda K, Kashiyama T, Ikeda Y, Nakagawa S, Sone K, Miyamoto Y, Hiraike H, Tanikawa M, Miyasaka A, Koso T, Matsumoto Y, Wada-Hiraike O, Kawana K, Kuramoto H, McCormick F, Aburatani H, Yano T, Kozuma S, Taketani Y.
    PLoS One; 2012 Jun 10; 7(5):e37431. PubMed ID: 22662154
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
    Xin P, Li C, Zheng Y, Peng Q, Xiao H, Huang Y, Zhu X.
    Drug Des Devel Ther; 2017 Jun 10; 11():1115-1126. PubMed ID: 28435223
    [Abstract] [Full Text] [Related]

  • 8. Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia.
    Gallagher EJ, Fierz Y, Vijayakumar A, Haddad N, Yakar S, LeRoith D.
    Oncogene; 2012 Jul 05; 31(27):3213-22. PubMed ID: 22037215
    [Abstract] [Full Text] [Related]

  • 9. Levels of p27 sensitize to dual PI3K/mTOR inhibition.
    Lee M, Theodoropoulou M, Graw J, Roncaroli F, Zatelli MC, Pellegata NS.
    Mol Cancer Ther; 2011 Aug 05; 10(8):1450-9. PubMed ID: 21646547
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells.
    Ji Y, Di W, Yang Q, Lu Z, Cai W, Wu J.
    Clin Lab; 2015 Aug 05; 61(8):1043-51. PubMed ID: 26427150
    [Abstract] [Full Text] [Related]

  • 11. Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.
    Kampa-Schittenhelm KM, Heinrich MC, Akmut F, Rasp KH, Illing B, Döhner H, Döhner K, Schittenhelm MM.
    Mol Cancer; 2013 May 24; 12():46. PubMed ID: 23705826
    [Abstract] [Full Text] [Related]

  • 12. Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer.
    Venkannagari S, Fiskus W, Peth K, Atadja P, Hidalgo M, Maitra A, Bhalla KN.
    Oncotarget; 2012 Nov 24; 3(11):1416-27. PubMed ID: 23232026
    [Abstract] [Full Text] [Related]

  • 13. Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma.
    Rosich L, Montraveta A, Xargay-Torrent S, López-Guerra M, Roldán J, Aymerich M, Salaverria I, Beà S, Campo E, Pérez-Galán P, Roué G, Colomer D.
    Oncotarget; 2014 Aug 30; 5(16):6788-800. PubMed ID: 25216518
    [Abstract] [Full Text] [Related]

  • 14. Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting.
    Pivonello C, Patalano R, Solari D, Auriemma RS, Frio F, Vitulli F, Grasso LFS, Di Cera M, De Martino MC, Cavallo LM, Cappabianca P, Colao A, Pivonello R.
    Endocrine; 2018 Dec 30; 62(3):663-680. PubMed ID: 30066286
    [Abstract] [Full Text] [Related]

  • 15. Targeting PI3K/mTOR Signaling Displays Potent Antitumor Efficacy against Nonfunctioning Pituitary Adenomas.
    Lee M, Wiedemann T, Gross C, Leinhäuser I, Roncaroli F, Braren R, Pellegata NS.
    Clin Cancer Res; 2015 Jul 15; 21(14):3204-15. PubMed ID: 25838390
    [Abstract] [Full Text] [Related]

  • 16. Targeting of PI3K/AKT/mTOR pathway to inhibit T cell activation and prevent graft-versus-host disease development.
    Herrero-Sánchez MC, Rodríguez-Serrano C, Almeida J, San Segundo L, Inogés S, Santos-Briz Á, García-Briñón J, Corchete LA, San Miguel JF, Del Cañizo C, Blanco B.
    J Hematol Oncol; 2016 Oct 20; 9(1):113. PubMed ID: 27765055
    [Abstract] [Full Text] [Related]

  • 17. Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.
    Fuereder T, Wanek T, Pflegerl P, Jaeger-Lansky A, Hoeflmayer D, Strommer S, Kuntner C, Wrba F, Werzowa J, Hejna M, Müller M, Langer O, Wacheck V.
    Clin Cancer Res; 2011 Aug 15; 17(16):5322-32. PubMed ID: 21712451
    [Abstract] [Full Text] [Related]

  • 18. Cotargeting the PI3K and RAS pathways for the treatment of neuroendocrine tumors.
    Valentino JD, Li J, Zaytseva YY, Mustain WC, Elliott VA, Kim JT, Harris JW, Campbell K, Weiss H, Wang C, Song J, Anthony L, Townsend CM, Evers BM.
    Clin Cancer Res; 2014 Mar 01; 20(5):1212-22. PubMed ID: 24443523
    [Abstract] [Full Text] [Related]

  • 19. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma.
    Zhu YR, Min H, Fang JF, Zhou F, Deng XW, Zhang YQ.
    Cancer Biol Ther; 2015 Mar 01; 16(4):602-9. PubMed ID: 25869769
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of PI3K-Akt-mTOR signal pathway dismissed the stimulation of glucose on goose liver cell growth.
    Wei S, Han C, He F, Song Q, Kang B, Liu H, Li L, Xu H, Zeng X.
    J Anim Physiol Anim Nutr (Berl); 2017 Oct 01; 101(5):e133-e143. PubMed ID: 27859698
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.